Merck started its Acceleron pursuit at $160 per share, but CEO Davis balked at paying more than $180 esagonowsky Tue, 10/12/2021 – 11:23 More: Merck started its Acceleron pursuit at 0 per share, but CEO Davis balked at paying more
read moreSpinoff or $54B sale? GlaxoSmithKline’s consumer health outfit draws buyout interest: report aliu Tue, 10/12/2021 – 10:47 More: Spinoff or B sale? GlaxoSmithKline's consumer health outfit draws buyout interest: report Source: fierce
read moreViatris to close former Novartis site in California in January, lay off 75 esagonowsky Tue, 10/12/2021 – 09:21 More: Viatris to close former Novartis site in California in January, lay off 75 Source: fierce
read moreMerck’s oral COVID-19 drug sees India’s Everest Organics hit start on production jkeenan Tue, 10/12/2021 – 08:34 More: Merck's oral COVID-19 drug sees India's Everest Organics hit start on production Source: fierce
read morePhase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens More: Amgen reveals new combination data for KRAS inhibitor Source: News
read moreThe new consumer healthcare company will be based at a newly built campus in Weybridge More: GSK plans UK headquarters for new consumer healthcare company Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals